Beam stock forecast.

Dec 1, 2023 · Scores. BEAM has an Altman Z-Score of 1.39 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy. Altman Z-Score. 1.39. Piotroski F-Score. 2. Detailed statistics for Beam Therapeutics Inc. (BEAM) stock, including valuation metrics, financial numbers, share information and more. The Beam Global stock price fell by -1.95% on the last day (Wednesday, 29th Nov 2023) from $6.14 to $6.02. During the last trading day the stock fluctuated 9.27% from a day low at $6.01 to a day high of $6.57. The price has fallen in 7 of the last 10 days and is down by -17.53% for this period. Volume fell on the last day along with the stock ...The Beam Therapeutics stock forecast for tomorrow is $ 27.79, which would represent a -6.02% loss compared to the current price. In the next week, the price of BEAM is expected to decrease by -2.93% and hit $ 28.70. As far as the long-term Beam Therapeutics stock forecast is concerned, here’s what our predictions are currently suggesting.Nov 1, 2023 · Stock Forecast for the Price of an Beam Therapeutics Share in Jan 2025. In January 2025, analysts believe the stock price will be $21.77. An increase of 14.09% compared to the previous month's estimate.

BEEM Stock 12 Months Forecast. $24.00. (228.09% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Beam Global in the last 3 months. The average price target is $24.00 with a high forecast of $40.00 and a low forecast of $12.00. The average price target represents a 228.09% change from the last price of $7.32. Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term ...

Find real-time BMRN - Biomarin Pharmaceutical Inc stock quotes, company profile, news and forecasts from CNN Business.Nov 25, 2023 · BEEM stock forecast for 2023 – 2027. Last updated: November 25, 2023. BEEM. Beam Global. 5.85 D 4.84% (0.27) Are you interested in Beam Global stocks prediction? If yes, then on this page you will find useful information about the dynamics of the BEEM stock price in 2022-2027. Is BEEM a good long term stock? When should I take profit in Beam ...

Nov 22, 2023 · According to the issued ratings of 3 analysts in the last year, the consensus rating for Beam Global stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for BEEM. The average twelve-month price prediction for Beam Global is $25.00 with a high price target of $25.00 and a low price target of $25.00. Infibeam Avenues Ltd., incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 5,667.88 Crore) operating in Services sector. Infibeam Avenues Ltd. key Products/Revenue Segments include Software Development Charges & Other Services for the year ending 31-Mar-2023.For the ...Scores. BEAM has an Altman Z-Score of 1.39 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy. Altman Z-Score. 1.39. Piotroski F-Score. 2. Detailed statistics for Beam Therapeutics Inc. (BEAM) stock, including valuation metrics, financial numbers, share information and more.This is hardly the only bullish review for Beam, although the company’s 6 recent analyst reviews do have an even split between Buys and Holds – making the consensus rating a Moderate Buy. BEEM shares have an average target of $29.50 and a current trading price of $15.09, suggesting ~95% upside going forward. (See BEAM stock forecast on ...

The first Wood-backed stock we’ll look at is Beam Therapeutics, ... Going by the $70.89 average target, the shares will climb ~62% higher in the year ahead. (See BEAM stock forecast)

Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid ...

Infibeam Avenues Ltd., incorporated in the year 2010, is a Mid Cap company (having a market cap of Rs 5,667.88 Crore) operating in Services sector. Infibeam Avenues Ltd. key Products/Revenue Segments include Software Development Charges & Other Services for the year ending 31-Mar-2023.For the ...Get the latest Infibeam Avenues Ltd (INFIBEAM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Next reporting date. February 14, 2024. EPS forecast (this quarter) $0.29. Annual revenue (last year) $11.1B. Annual profit (last year) $432.0M. Net profit margin.Second, Amgen is forecast to post a respectable 4.1% rise in annual sales in 2022. ... A deeply undervalued gene-editing stock. Beam Therapeutics (BEAM 0.68%) ...In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.

A high-level overview of Beam Therapeutics Inc. (BEAM) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Nov 29, 2023 · The Beam Global stock price fell by -1.95% on the last day (Wednesday, 29th Nov 2023) from $6.14 to $6.02. During the last trading day the stock fluctuated 9.27% from a day low at $6.01 to a day high of $6.57. The price has fallen in 7 of the last 10 days and is down by -17.53% for this period. Volume fell on the last day along with the stock ... Key Points. Cathie Wood is an icon in the world of disruptive tech. Her firm ARK Invest holds positions in Beam Therapeutics, COMPASS Pathways, and 908 Devices. Wall Street analysts have ...Following the upgrade, the consensus from 13 analysts covering Beam Therapeutics is for revenues of US$60m in 2023, implying a small 2.2% decline in sales compared to the last 12 months. Per-share ...Find real-time ROKU - Roku Inc stock quotes, company profile, news and forecasts from CNN Business.Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term ...

TTOO. T2 Biosystems, Inc. Common Stock. $0.56 +0.1067 +23.54%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market ... View the latest Verizon Communications Inc. (VZ) stock price, news, historical charts, analyst ratings and financial information from WSJ.

SmartAssetPaid Partner. Find real-time FSR - Fisker Inc stock quotes, company profile, news and forecasts from CNN Business.Find the latest Ion Beam Applications SA (IBAB.BR) stock quote, history, news and other vital information to help you with your stock trading and investing.As the old saying goes, “Forewarned is forearmed.” This sentiment holds true when it comes to weather forecasting as well. One of the primary advantages of a 30-day extended weather forecast is the ability to plan ahead with confidence.Mar 5, 2023 · Following the upgrade, the consensus from 13 analysts covering Beam Therapeutics is for revenues of US$60m in 2023, implying a small 2.2% decline in sales compared to the last 12 months. Per-share ... It’s difficult to put a positive spin on the current state of the stock market. While 2022’s action has seen moments of relief, for the most part, the trend has been resolutely downbeat, as reflected in the main indexes’ performances. All are down by at least double-digits; the tech-heavy NASDAQ’s 27% drop has been the most acute, while the …Real Money Technical Analyst Bruce Kamich gives his updated 2023 market forecast Employees of theStreet are prohibited from trading individual securities. Here's how traders can play this biotech stock. The charts of the building materials ...Dec 1, 2023 · Beam Therapeutics last released its earnings results on November 8th, 2023. The reported ($1.22) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.11. The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $17.09 million. Its revenue was up 8.9% on a year-over-year basis. Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference. CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive …Tomorrow's movement Prediction of Infibeam Incorp. INFIBEAM appears to be in uptrend. And this trend seems to be continuing further. Price is above an important level of 20.84 on charts, and as long as price remains …

NTLA Stock 12 Months Forecast. Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $78.65 with a high forecast of $136.00 and a low forecast of $31.00. The average price target represents a 151.68% change from the last price of $31.25.

A high-level overview of Beam Therapeutics Inc. (BEAM) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Fiscal Q3 2023 ended 9/30/23. Get the latest Beam Therapeutics Inc (BEAM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading... Lockheed Martin (NYSE:LMT) pays an annual dividend of $12.00 per share and currently has a dividend yield of 2.69%. The company has been increasing its dividend for 21 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 43.84%.Future criteria checks 1/6. Beam Therapeutics's earnings are forecast to decline at 11.2% per annum while its annual revenue is expected to grow at 12.2% per …Mar 21, 2023 · According to 4 analyst offering 12-month price targets in the last 3 months, Beam Therapeutics has an average price target of $70.25 with a high of $105.00 and a low of $37.00. Below is a summary ... Stock Forecast Based On a Predictive Algorithm | I Know First | Disclaimer: I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any …It’s difficult to put a positive spin on the current state of the stock market. While 2022’s action has seen moments of relief, for the most part, the trend has been resolutely downbeat, as reflected in the main indexes’ performances. All are down by at least double-digits; the tech-heavy NASDAQ’s 27% drop has been the most acute, while the …“This call aims to develop an USPL that is ruggedized enough to begin testing in relevant Army environments,” it continued. The Army also began testing a prototype laser weapon for close-range air defense in May, the Defense Post reported.The high-energy laser will be able to locate, lock on, track and destroy aerial threats in just seconds.Beam Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030. In the last three years, Beam Therapeutics's EPS has grown, increasing from $-2.49 to $-4.13 – an increase of 65.86%. For the next year, 13 analysts project Beam Therapeutics's EPS to drop by 3.39%, reaching $-3.99. By 2030, professionals believe that Beam Therapeutics's ...

Jun 13, 2022 - Beam Therapeutics stock forecast & analyst price target predictions based on 9 analysts offering 12-months price targets for BEAM in the last 3 months. Pinterest. Today. Watch. Shop. Explore. When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with ...Get the latest Beam Therapeutics Inc (BEAM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …It’s difficult to put a positive spin on the current state of the stock market. While 2022’s action has seen moments of relief, for the most part, the trend has been resolutely downbeat, as ...Instagram:https://instagram. mad money kramerstock price bbbykennedy 1964 half dollar worthspy etf holdings Stock Splits: Mergers & Acquisitions: Business Services/Equipment M&A Construction M&A General Contractors & Builders M&A Consumer Goods M&A Sporting Goods & Activities M&A Office Supplies M&A Food & Beverage M&A Beverages & Wineries M&A Cigarettes & Tobacco M&A Marijuana Stocks M&A Apparel Stores M&A Department Stores M&A … ambetter insurance ratinghow to invest in watches Beam Therapeutics last released its earnings results on November 8th, 2023. The reported ($1.22) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.11. The firm had revenue of $17.20 million for the quarter, compared to analyst estimates of $17.09 million. Its revenue was up 8.9% on a year-over-year basis. gdxj holdings BEAM Stock 12 Months Forecast. $43.44. (58.25% Upside) Based on 11 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $43.44 with a high forecast of $75.00 and a low forecast of $19.00. The average price target represents a 58.25% change from the last price of $27.45.Based on those assumptions, my modeling says Aeva could do about $10 in earnings per share by 2030. A simple 20X multiple on that implies a long-term potential price target here of $200. The AEVA ...